Early Administration of L-carnitine in Hemodialysis Patients
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Hemodialysis is a cause of carnitine deficiency. The deficiency of carnitine induces an
anemia by an increase fragility of the red blood cells, a muscular fatigue and a cardiac
dysfunction. We proposed to evaluate the benefit of an early administration of L-carnitine in
hemodialysis patients. The patients should be included in the first month after the start of
chronic hemodialysis, randomized to receive L-carnitine or placebo and should be followed-up
during one year.